MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Lewy bodies"

  • 2025 International Congress

    Efficacy of Stimulant Use for Cognitive Fluctuations in Lewy Body Dementia: A Case Study

    L. Lopez, A. Petrov, Z. Afshari (Glenview, USA)

    Objective: To evaluate the effectiveness of stimulants in reducing cognitive fluctuations in Lewy Body Dementia (LBD). Background: Lewy Body Dementia (LBD) is the 2nd most…
  • 2025 International Congress

    Sex differences in regional densities of Lewy body pathology

    C. Tremblay, S. Chiu, G. Serrano, C. Adler, H. Shill, E. Driver-Dunckley, S. Mehta, C. Belden, D. Shprecher, Y. Zeighami, M. Dadar, A. Atri, T. Beach, P. Choudhury (Montreal, Canada)

    Objective: To assess sex differences in regional Lewy body pathology densities and their clinical correlations in cases with Lewy body (LB) pathology at autopsy. Background:…
  • 2025 International Congress

    Lewy Pathology in the Peripheral Nervous System of SNCA Duplication

    G. Beck, M. Yamadera, A. Tarutani, Y. Yonenobu, M. Hasegawa, S. Murayama, H. Mochizuki (Suita, Japan)

    Objective: This study aimed to investigate the degree, distribution, and biochemical profile of phosphorylated α-synuclein (p-α-syn) in the peripheral nervous system of patients with SNCA…
  • 2025 International Congress

    Patient-derived α-synuclein seed amplification as a tool for evaluating small molecule aggregation inhibitors for Parkinson’s disease and Lewy Body Dementia therapeutics

    K. Luk, B. Li, S. Song, N. Newman (Cambridge, USA)

    Objective: To validate on-target engagement of disease-relevant ⍺-synuclein (a-syn) aggregates by WTX-607, WaveBreak’s small-molecule clinical candidate for Parkinson’s disease (PD) and Lewy body dementia (LBD),…
  • 2025 International Congress

    Validation of CSF Alpha-synuclein SAA in an Autopsy Cohort with Systemic Assessment of Lewy Pathology Including the Body

    M. Kurihara, T. Matsubara, K. Satoh, A. Arakawa, M. Hara, K. Kanemaru, A. Iwata, S. Murayama, Y. Saito (Tokyo, Japan)

    Objective: Based on the recent recommendations by international neuropathologists [1], we attempted to evaluate the diagnostic accuracy of cerebrospinal fluid (CSF) alpha-synuclein (α-syn) seeding amplification…
  • 2025 International Congress

    Sex Differences for Autopsy-Confirmed Prodromal Lewy Body Dementia

    F. Dino, L. Gunn-Sandell, A. Tsai, D. Carter, Y. Wang, E. Bayram (Aurora, USA)

    Objective: To assess sex differences in prodromal Lewy body dementia (LBD) compared to Alzheimer’s disease (AD) Background: Identifying LBD at the prodromal stage can provide…
  • 2025 International Congress

    Design of the Phase 2, Double-Blind, Placebo-Controlled, Multicenter Study Investigating the Efficacy and Safety of ACP-204, a Novel 5-HT2A Inverse Agonist, in Adults With Lewy Body Dementia Psychosis

    R. Nunez, S. Friend, B. Howell, S. Pathak, B. Dirks, X. Feng, V. Abler (San Diego, USA)

    Objective: To present the design for a study of ACP-204 efficacy and safety in adults with Lewy body dementia psychosis (LBDP), including Parkinson’s disease dementia…
  • 2025 International Congress

    Visual processing impairments are predictive of dementia in Lewy Body disease

    E. Mccann, F. Coleman, A. Fazlollahi, S. Lee, J. O'Sullivan, P. Nestor (Herston, Australia)

    Objective: To characterise visual processing impairments as an early feature of dementia in Lewy Body disease (LBD). Background: Occipital and posterior parieto-temporal hypometabolism is a…
  • 2025 International Congress

    Alpha-Synuclein Accumulation-Attenuating Effect of Brain-Derived Neurotrophic Factor in Primary Cell Culture Model of Parkinson’s Disease

    I. Hlushchuk, MT. Airavaara (Helsinki, Finland)

    Objective: To explore the role of neurotrophic signaling pathways in modulating the effect of brain-derived neurotrophic factor (BDNF) on pre-formed fibrils (PFFs)- induced alpha-synuclein (aSyn)…
  • 2025 International Congress

    The Impact of Microgravity and Herpes Simplex Virus 1 on Parkinson’s Neurodegeneration and HERV Expression

    ER. Simula, S. Jasemi, D. Cossu, I. Cossu, M. Fais, M. Noli, LA. Sechi (Sassari, Italy)

    Objective: The present abstract aims to investigate the impact of viral infections and microgravity exposure in the context of Parkinson’s disease (PD). Background: PD is…
  • 1
  • 2
  • 3
  • …
  • 10
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley